PACIFIC EDGE LIMITED (PEB)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

PEB - PACIFIC EDGE LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: March
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.04
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.082

07 Dec
2023

-0.004

OPEN

$0.09

-4.65%

HIGH

$0.09

50,055

LOW

$0.08

TARGET
$0.50 509.8% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . HLA . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PGC . PME . RMD . SOM . TRJ . UBI . VHT . VTI .
FNARENA'S MARKET CONSENSUS FORECASTS
PEB: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx - 3.0 - 3.2 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2023 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-3.0
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx17.9 M
Book Value Per Share xxxxxxxxxxxxxxx9.5
Net Operating Cash Flow xxxxxxxxxxxxxxx-23.3 M
Net Profit Margin xxxxxxxxxxxxxxx-137.46 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-27.65 %
Return on Invested Capital xxxxxxxxxxxxxxx-27.47 %
Return on Assets xxxxxxxxxxxxxxx-25.63 %
Return on Equity xxxxxxxxxxxxxxx-27.65 %
Return on Total Capital xxxxxxxxxxxxxxx-33.76 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-25.0 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx73 M
Price To Book Value xxxxxxxxxxxxxxx4.21

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx2.7 M
Capex % of Sales xxxxxxxxxxxxxxx14.83 %
Cost of Goods Sold xxxxxxxxxxxxxxx9 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx39 M
Research & Development xxxxxxxxxxxxxxx8 M
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

xx/xx/xxxx

3

xxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Macquarie

26/05/2023

3

Neutral

-

-

Macquarie notes FY23 results revealed solid revenue growth while Pacific Edge provided no quantitative guidance.

The broker believes the company is allocating capital in the right way but a potential loss of coverage is a significant overhang for investors.

Macquarie warns investors should stay cautious until there is clarity around the Novitas LCD proposal, which has potential to disrupt reimbursement for patients with Medicare and Medicare Advantage plans in the US.

Neutral rating and NZ$0.48 target retained. Estimates for earnings per share are raised by 5% and 4% for FY24 and FY25, respectively.

FORECAST
Macquarie forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -3.30 cents.
Macquarie forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -2.20 cents.
Access Stockbroker Research History >

PEB STOCK CHART

FNArena News on PEB

1
July In Review: Energy And Banks Drive Gains

Aug 03 2023 - Australia
2
FNArena Corporate Results Monitor – 02-06-2023

Jun 02 2023 - Australia
3
Australian Broker Call *Extra* Edition – Jan 25, 2023

Jan 25 2023 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Oct 25, 2022

Oct 25 2022 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Aug 09, 2022

Aug 09 2022 - Daily Market Reports

Latest Medical Equipment & Devices News

1
Dr Boreham’s Crucible: Pro Medicus

Oct 23 2023 - Australia
2
Dr Boreham’s Crucible: Cyclopharm

Oct 09 2023 - Small Caps
3
Dr Boreham’s Crucible: Painchek

Sep 11 2023 - Small Caps
4
Margins Signal Integral Diagnostics Recovery

Sep 07 2023 - Australia
5
ResMed: Finding A Base?

Aug 15 2023 - Technicals
6
August Turns ResMed Into Nigel NoMates

Aug 09 2023 - Australia
7
Dr Boreham’s Crucible: Lumos Diagnostics

Jun 19 2023 - Small Caps
8
Fisher & Paykel Healthcare: Lower Margin, Higher Spending

May 30 2023 - Australia
9
Dr Boreham’s Crucible: Impedimed

May 08 2023 - Small Caps
10
Treasure Chest: ResMed’s Benevolent Monopoly

May 01 2023 - Treasure Chest